These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31823527)

  • 1. Pharmacokinetics, Pharmacodynamics, and Safety of a Single Escalating Dose and Repeated Doses of Rasagiline Transdermal Patch in Healthy Chinese Subjects.
    Wang M; Zhou W; Zhang Q; Zong S; Lv C
    Clin Pharmacol Drug Dev; 2020 Jul; 9(5):602-609. PubMed ID: 31823527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, Pharmacodynamics, and Safety of Rasagiline Transdermal Patch: A Preliminary Study in Healthy Chinese Subjects.
    Zhou W; Lv C; Zhang Q; Zong S; Wang M
    Clin Drug Investig; 2018 Feb; 38(2):125-133. PubMed ID: 29159774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor.
    Thébault JJ; Guillaume M; Levy R
    Pharmacotherapy; 2004 Oct; 24(10):1295-305. PubMed ID: 15628826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative single-dose pharmacokinetics of rasagiline in minipigs after oral dosing or transdermal administration via a newly developed patch.
    Lin Y; Zou Y; Lin J; Zhang T; Deng J
    Xenobiotica; 2013 Aug; 43(8):705-10. PubMed ID: 23339547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo.
    Meier-Davis SR; Dines K; Arjmand FM; Hamlin R; Huang B; Wen J; Christianson C; Shudo J; Nagata T
    Cutan Ocul Toxicol; 2012 Dec; 31(4):312-7. PubMed ID: 22515841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
    Chen JJ; Ly AV
    Am J Health Syst Pharm; 2006 May; 63(10):915-28. PubMed ID: 16675649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
    Goren T; Adar L; Sasson N; Weiss YM
    J Clin Pharmacol; 2010 Dec; 50(12):1420-8. PubMed ID: 20445015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of single and multiple doses of rasagiline in healthy Japanese and caucasian subjects.
    Elgart A; Rabinovich-Guilatt L; Eyal E; Gross A; Spiegelstein O
    Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):273-284. PubMed ID: 30218626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson's disease: a thorough QT/QTc study.
    Mendzelevski B; Sprenger CR; Spiegelstein O; Rabinovich-Guilatt L
    Int J Clin Pharmacol Ther; 2014 Mar; 52(3):192-201. PubMed ID: 24447649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan.
    Hattori N; Takeda A; Takeda S; Nishimura A; Kitagawa T; Mochizuki H; Nagai M; Takahashi R
    Parkinsonism Relat Disord; 2019 Mar; 60():146-152. PubMed ID: 30205936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
    deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
    Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
    Olanow CW; Rascol O; Hauser R; Feigin PD; Jankovic J; Lang A; Langston W; Melamed E; Poewe W; Stocchi F; Tolosa E;
    N Engl J Med; 2009 Sep; 361(13):1268-78. PubMed ID: 19776408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of rasagiline in the treatment of Parkinson's disease.
    Leegwater-Kim J; Bortan E
    Clin Interv Aging; 2010 May; 5():149-56. PubMed ID: 20517484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rasagiline.
    Siddiqui MA; Plosker GL
    Drugs Aging; 2005; 22(1):83-91; discussion 93-4. PubMed ID: 15663351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, Tolerability, and Bioequivalence of Two Formulations of Rotigotine in Healthy Chinese Subjects.
    Liu Y; Tomlinson B; Guo J; Asgharnejad M; Bauer L; Surmann E; Guo X; Elshoff JP
    Clin Ther; 2018 Jul; 40(7):1108-1121.e8. PubMed ID: 30098648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
    Rabey JM; Sagi I; Huberman M; Melamed E; Korczyn A; Giladi N; Inzelberg R; Djaldetti R; Klein C; Berecz G;
    Clin Neuropharmacol; 2000; 23(6):324-30. PubMed ID: 11575866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selegiline and rasagiline: twins or distant cousins?
    Knudsen Gerber DS
    Consult Pharm; 2011 Jan; 26(1):48-51. PubMed ID: 21224199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.